Kymera Therapeutics
Kymera Therapeutics' revenue fell 16.7% to $39 million in fiscal 2025. Its operating margin was −891.1%, down from −555.8% a year earlier. Free cash flow was −$234 million. The diluted share count rose 12.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Kymera Therapeutics does
Kymera Therapeutics is a clinical-stage biopharmaceutical company, which means it tests its medicines in people and has none approved for sale. It works on targeted protein degradation, an approach in which a small-molecule medicine uses the body's natural cellular recycling system to remove a protein that drives disease, instead of just blocking it.
Its work is mainly aimed at immune and inflammatory diseases. Kymera wants to offer a daily pill that works like the injected biologic drugs now used for many of these patients. Its publicly disclosed programs target three proteins: STAT6, IRF5 and IRAK4. Its lead medicine in the STAT6 program, KT-621, is in Phase 2b trials in adults and adolescents with moderate to severe atopic dermatitis (a skin condition) and in adults with moderate to severe asthma. KT-579, an oral IRF5 degrader, has started a Phase 1 trial.
Kymera says it expects to start clinical testing of at least one new molecule each year, and it hopes to become a fully integrated drug company. It was formed in 2015.
Its biggest risks, as it describes them
- It is a clinical-stage company, so it is hard to judge its business to date or its future.
- It has lost money since it began and expects more losses for the foreseeable future.
- It will need substantial additional money, and raising it may dilute its shareholders.
- Its drug candidates may fail in clinical trials or fail to win regulatory approval.
- Targeted protein degradation is a new kind of medicine, so its development path is hard to predict.
Income statement
Kymera Therapeutics lost money in fiscal 2025: a net loss of $311 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 442 | 407 | 375 | 489 | 848 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −636.3x | −900.9x | −1,021.8x | −1,270.1x | −1,119.9x |
| Current ratio | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
| Quick ratio | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
Cash flow
Projections
Project Kymera Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $172.5 million of Kymera Therapeutics shares on the open market, and 11 insiders sold $461.2 million, $263.0 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Brian AdamsChief Legal Officer | Sold | 6,371 | $116.83 | $744,297 | Form 4 |
| Jul 7, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 50,000 | $119.00 | $6.0 million | Form 4 |
| Jul 1, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 80,000 | $115.30 | $9.2 million | Form 4 |
| Jul 1, 2026 | Noah GoodmanChief Business Officer | Sold plan | 3,389 | $114.29 | $387,329 | Form 4 |
| Jun 30, 2026 | Bruce N. JacobsChief Financial Officer | Sold plan | 77,109 | $114.97 | $8.9 million | Form 4 |
| Jun 29, 2026 | Bruce BoothDirector | Sold plan | 45,367 | $107.06 | $4.9 million | Form 4 |
| Jun 29, 2026 | Bruce BoothDirector | Sold plan | 31,283 | $109.48 | $3.4 million | Form 4 |
| Jun 26, 2026 | Biotechnology Value Fund II LpDirector | Sold | 1,630,658 | $106.50 | $173.7 million | Form 4 |
| Jun 26, 2026 | Bruce BoothDirector | Sold plan | 467,878 | $110.29 | $51.6 million | Form 4 |
| Jun 25, 2026 | Bruce BoothDirector | Sold plan | 285,684 | $121.86 | $34.8 million | Form 4 |
| Jun 25, 2026 | Bruce BoothDirector | Sold plan | 262,637 | $115.39 | $30.3 million | Form 4 |
| Jun 25, 2026 | Noah GoodmanChief Business Officer | Sold plan | 5,000 | $114.00 | $570,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −106.9% | −480.6% | −614.3% |
| Altman Z'' | 1.00 | 4.82 | 9.79 |
| Accruals ratio | −7.5% | −3.8% | −5.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Kymera Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics | FY25 | −16.7% | −891.1% | −597.6% | — | — | — | |
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | Compare |
| Wave Life Sciences | FY25 | −60.5% | −504.1% | −440.5% | — | — | — | Compare |
| Protagonist Therapeutics | FY25 | −89.4% | −343.6% | 121.9% | — | — | — | Compare |
| Septerna | FY25 | 4,174.5% | −148.6% | 238.7% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3 | 34 | 73 | 47 | 79 | 47 | 39 |
| Revenue growth | — | 1,060.0% | 114.0% | −35.7% | 67.8% | −40.1% | −16.7% |
| Gross profit | — | — | — | 0 | 0 | 0 | 0 |
| Research and development | 37 | 62 | 137 | 164 | 189 | 240 | 317 |
| Operating income | −42 | −46 | −100 | −161 | −166 | −262 | −349 |
| Net income | −41 | −46 | −100 | −155 | −147 | −224 | −311 |
| Diluted EPS (US$) | −24.28 | −3.15 | −2.09 | −2.87 | −2.52 | −2.98 | −3.69 |
| Diluted shares (millions) | 2 | 17 | 48 | 54 | 58 | 75 | 84 |
| Cash flow | |||||||
| Cash from operations | 18 | 88 | −129 | −153 | −103 | −194 | −233 |
| Capital expenditure | 0 | 9 | 2 | 3 | 34 | 13 | 1 |
| Free cash flow | 17 | 79 | −131 | −156 | −137 | −207 | −234 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 5 | 25 | 36 | 43 | 55 | 60 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 92 | 296 | 442 | 407 | 375 | 489 | 848 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 117 | 487 | 606 | 603 | 576 | 978 | 1,743 |
| Total liabilities | 82 | 203 | 146 | 113 | 181 | 142 | 163 |
| Shareholders' equity | −74 | 284 | 460 | 490 | 395 | 836 | 1,580 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating margin | −1,438.5% | −136.1% | −138.0% | −344.4% | −210.6% | −555.8% | −891.1% |
| Net margin | −1,405.8% | −134.0% | −137.6% | −330.6% | −187.0% | −475.6% | −794.0% |
| Free cash flow margin | 592.1% | 232.2% | −179.2% | −333.0% | −174.7% | −440.5% | −597.6% |
| Rule of 40 (growth + FCF margin) | — | 1,292.2% | −65.2% | −368.7% | −106.9% | −480.6% | −614.3% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −43.5% | −27.0% | −32.6% | −33.2% | −36.4% | −25.8% |
| Return on assets | — | −15.1% | −18.3% | −25.6% | −24.9% | −28.8% | −22.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — |